Reference
Janssen Pharmaceutical Companies, et al. Darzalex (daratumumab) and risk of reactivation of hepatitis B virus. Internet Document : 26 Jun 2019. Available from: URL: https://assets.publishing.service.gov.uk/media/5d2dbdbbe5274a14e7135640/Darzalex_DHPC-June_2019.pdf
Rights and permissions
About this article
Cite this article
Risk of hepatitis B reactivation with daratumumab. Reactions Weekly 1763, 5 (2019). https://doi.org/10.1007/s40278-019-65097-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-65097-5